Table 1.
Study population baseline characteristics
| Baseline characteristics (n = 500) | |||
|---|---|---|---|
|
Demographics |
Medication previous to TEE |
||
| Age (years) |
69 ± 10 |
Oral Anticoagulation |
40.6% (203) |
| Age ≥ 75 years |
31% (155) |
Antiplatelet agents |
46.4% (232) |
| Age 65–74 years |
39.8% (199) |
1-3 doses of enoxaparine |
33.8% (169) |
| Body Mass Index (Kg/m2) |
26.6 ± 8.8 |
Echocardiographic characterization |
|
| Female gender |
34.2% (171) |
LA AP diameter (cm) |
4.7 ± 0.7 |
|
Clinical data |
LA area (cm2) |
27.6 ± 7.1 |
|
| Hypertension |
81.8% (409) |
LA ellipsoid volume (cm3) |
74.1 ± 29.0 |
| Diabetes |
23.6% (118) |
LA 1P area-length volume (cm3) |
113.8 ± 47.7 |
| Previous Stroke/TIA |
14.8% (74) |
LA 2P area-length volume (cm3) |
104.1 ± 38.1 |
| Congestive heart failure |
54.8% (274) |
LV ejection fraction ≥55% |
73.6% (368) |
| Vascular diseasea |
52% (260) |
LAA thrombus |
11.1% (55) |
| CHADS2 |
1.9 ± 1.2 |
LAA low flow velocities |
13.2% (66) |
| CHA2DS2-VASc |
3.2 ± 1.7 |
Dense SEC |
24% (120) |
| Pacemaker or ICD |
19.6% (98) |
LA ABN |
29.6% (148) |
|
Estimated current AF episode duration |
Laboratorial evaluation |
||
| ≤ 48 hours |
7% (35) |
Haemoglobin (g/dL) |
13.2 ± 1.8 |
| < 1 week |
19.6% (98) |
Platelets (103/μL) |
219.7 ± 85.5 |
| < 1 month |
36% (180) |
INR |
1.5 ± 0.8 |
| > 6 months |
35.8% (179) |
INR ≥ 2.0 |
20.8% (104) |
| > 1 year | 26.8% (134) | GFR (mL/min/1.73 m2) | 62.4 ± 33.0 |
Legend: GFR – glomerular filtration rate; ICD - implantable cardioverter defibrillator; INR – international normalized ratio; LV – left ventricle; TIA – transient ischaemic attack.
aVascular disease is defined as having at least one of the following: myocardial infarctions, peripheral artery disease, and complex aortic plaque.